Time to accumulate more IMO...We are currently in a 'lul' waiting for results on those treated in Ph2, and also on a whole slew of those treated since US sites came on board. Great data on Ph2 trial is the first driver for me. Then there is the COVID angle, where we continue to see new 'variants' for which approved vaccines may or may not be effective, the jury is still out. I happen to believe that TLD1433 will ultimately prove to be extremely effective against these and future viruses, so IMO it's just a matter of time until the NML comes to this conclusion, sometime before end of 2021.
I've decided to move out of one or two stocks that I still believe have upside but have flattened or shown little activity recently. IMO, TLT at $0.22 offers a much better risk/reward ratio over the next 12-18 months. JMHO, DYODD.